BSEM on XNAS, Health Care, BioStem Technologies, Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 84% in a year as latest quarter revenue dropped 27% to $7.6M.
BadTwo share registrations S-1 and two private offerings in 90 days
WatchCompanies filing S-1 trailed sector by median 23.8 points over six months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
Industry
Biological products, (no diagnostic substances) (Health Care)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $7.6M, net loss $11.4M.
30 Jun 2025RevenueNet incomeNet losstallest bar $11.4M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$7.6M
-$11.4M
30 Jun 2026
$7.9M
-$9.0M
30 Sep 2025
$10.5M
$761K
30 Jun 2025
$11.0M
$11K
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
–
–
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$971K
$27.2M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$1.0M
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$29K
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.05
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$0.96
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
–
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.66
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-27%
$7.6M vs $10.5M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-100%
$0 vs $2.4M (quarter ended 30 Sep 2026)
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$14K
bought $0, sold $14K
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
9.1%
1.7M shares held by 13F filers (30 Sep 2026) of 19.2M outstanding (11 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
1.5%
287K shares sold short (30 Oct 2026) of 19.2M outstanding (11 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
1.5
287K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-14%
334K shares sold short in the report before, 287K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
36%
36% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$300K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
4
4 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
2.0×
4 articles in the last 7 days; its usual week has 2.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 554K, 2.4× a year earlier
Price $0.64 on 20 Nov 2026, -84% over 12 months (12-month range $0.64 to $8.20)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $14K in the last 12 months (the 12 months before: $0).Revenue per quarter. Revenue $7.6M in the latest quarter, -27% on a year earlier.Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.Institutional holders (13F filers). 23 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.Lobbying spend. Lobbying spend: $300K published in the last 12 months, -23% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Reported lobbying spend: $60K in Q2 2026, $120K in Q1 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
12 May 2026
Ended
Ballard Partnersfor Biostem Technologies
Advocated for medicare reimbursement for skin substitutes that are used to heal wounds caused from diabetes.Medicare/Medicaid
had 554K shares sold short in the 14 Aug 2026 report, 2.4× the same report last year.
Same report last year: 234K; its normal report is 378K.
See the evidence
This period
554K (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
378K
Typical spread (median absolute deviation)
30K
How far from its usual level
+3.5
Same report last year
234K
History used
3,150 days
the 14 Aug 2026 report24 earlier reportsnormal: 378K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Not listed: 9 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001658678
Ticker
BSEM
Domain
biostemtechnologies.com
Employer name
Biostem Technologies (1 unverified)
Fein
27-0400416 (1 unverified)
Hq location
FL|POMPANO BEACH|33604 (1 unverified)
Lobbying client
biostem technologies
Name
BioStem Technologies, Inc.
DOL H-1B labor condition applications and PERM certifications2 data points6 Apr 2026 to 6 Apr 2026
Federal lobbying disclosures (LDA)2 records, 24 data points1 Aug 2024 to 30 Jun 2026
SEC Form 13F institutional holdings9 data points30 Sep 2026 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)19 records1 Feb 2016 to 12 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)62 data points31 Dec 2024 to 11 Nov 2026
SEC Form 4 insider transactions1 record, 4 data points19 Nov 2026 to 19 Nov 2026
FINRA short interest (twice monthly)539 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)150 data points7 Aug 2026 to 20 Nov 2026